Abstract
Background. After immunization with serogroup C meningococcal (MenC) conjugate vaccine, antibody responses and vaccine effectiveness are sustained in adolescents, in contrast to rapid waning in young children. We investigated the persistence of serum bactericidal antibody (SBA) titers in children 6 years after immunization with MenC vaccine (primed between 2 months and 6 years of age). The response to a Haemophilus influenzae type b-MenC conjugate (Hib-MenC) booster was also measured. Methods. A phase 4 clinical trial was conducted among 250 healthy 6-12-year-old children. SBA titers were measured before, 1 month after, and 1 year after Hib-MenC administration. The correlate of protection was an SBA titer of ≥8. Results. An SBA titer of ≥8 was observed in 61 (25% [95% confidence interval {CI}, 20%-30%]) of 244 participants (mean age, 9.1 years; mean interval since MenC immunization, 6.75 years). The proportion with an SBA titer of ≥8 and the SBA geometric mean titer increased with age, from 12% (95% CI, 4%-23%) to 48% (95% CI, 29%-67%) and from 2.90 (95% CI, 2.11-3.99) to 17.20 (95% CI, 6.80-43.5), respectively, from a mean age of 7.0 to 12.1 years. One month after the Hib-MenC booster, all participants had an SBA titer of ≥8, which was sustained in 99.6% at 1 year. Conclusions. As a result of waning antibody, the majority of 6-12-year-old children in the United Kingdom have inadequate serological protection against MenC. The persistence of MenC immunity and the response to a Hib-MenC booster is dependent on age at priming. A booster was highly effective in this cohort and could sustain population immunity against MenC disease. Trial registration. Current Controlled Trials (http://www.controlled-trials.com) identifier: ISRCTN72858898.
| Original language | English |
|---|---|
| Pages (from-to) | 1601-1610 |
| Number of pages | 10 |
| Journal | Clinical Infectious Diseases |
| Volume | 50 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published - 15 Jun 2010 |
Bibliographical note
Funding Information:Potential conflicts of interest. The study was partly funded by GlaxoSmithKline. A.J.P. has conducted clinical trials on behalf of Oxford University sponsored by manufacturers of vaccines. A.J.P. does not accept any personal payments from vaccine manufacturers; honoraria, travel expenses, and grants for support of educational activities are paid to an educational/administrative fund held by the Department of Paediatrics, University of Oxford. R.B. has received assistance to attend scientific meetings from Wyeth, Novartis, Sanofi Pasteur, and Baxter Bioscience and has served as an ad hoc consultant for Wyeth, GlaxoSmithKline, Novartis, Sanofi Pasteur, and Baxter Bioscience. Industry honoraria received for consulting, lecturing, and writing are paid directly into the Central Manchester and Manchester Children’s University Hospitals National Health Service Trust endowment fund. R.B. has performed contract research on behalf of the Health Protection Agency (funded by Wyeth, Novartis Vaccines, Baxter Bioscience, GlaxoSmithKline, Sanofi Pasteur, Alexion Pharmaceuticals, Emergent Europe, and Merck). All other authors: no conflicts.
